CN108588083A - 适用于家蚕表达的改造血小板衍生生长因子基因及其表达载体和应用 - Google Patents
适用于家蚕表达的改造血小板衍生生长因子基因及其表达载体和应用 Download PDFInfo
- Publication number
- CN108588083A CN108588083A CN201810344164.4A CN201810344164A CN108588083A CN 108588083 A CN108588083 A CN 108588083A CN 201810344164 A CN201810344164 A CN 201810344164A CN 108588083 A CN108588083 A CN 108588083A
- Authority
- CN
- China
- Prior art keywords
- growth factor
- expression
- expression vector
- gene
- silkworm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000255789 Bombyx mori Species 0.000 title claims abstract description 47
- 230000014509 gene expression Effects 0.000 title claims abstract description 44
- 239000013604 expression vector Substances 0.000 title claims abstract description 29
- 230000009466 transformation Effects 0.000 title claims abstract description 17
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 title claims abstract description 16
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 35
- 239000003102 growth factor Substances 0.000 claims abstract description 18
- 238000012216 screening Methods 0.000 claims abstract description 13
- 108010013296 Sericins Proteins 0.000 claims abstract description 11
- 239000003550 marker Substances 0.000 claims abstract description 8
- 239000003623 enhancer Substances 0.000 claims abstract description 7
- 210000004907 gland Anatomy 0.000 claims abstract description 7
- 239000002773 nucleotide Substances 0.000 claims abstract description 4
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 46
- 239000011780 sodium chloride Substances 0.000 claims description 23
- 210000001772 blood platelet Anatomy 0.000 claims description 22
- 230000009261 transgenic effect Effects 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 13
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 7
- 238000000746 purification Methods 0.000 claims description 7
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 6
- 239000007853 buffer solution Substances 0.000 claims description 6
- 229960002897 heparin Drugs 0.000 claims description 6
- 229920000669 heparin Polymers 0.000 claims description 6
- 238000005349 anion exchange Methods 0.000 claims description 5
- 238000005341 cation exchange Methods 0.000 claims description 5
- 239000003480 eluent Substances 0.000 claims description 5
- 108091008146 restriction endonucleases Proteins 0.000 claims description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004202 carbamide Substances 0.000 claims description 4
- 235000013601 eggs Nutrition 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 4
- 239000003292 glue Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 230000005058 diapause Effects 0.000 claims description 3
- 230000029087 digestion Effects 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 238000011144 upstream manufacturing Methods 0.000 claims description 3
- 230000012447 hatching Effects 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 abstract description 5
- 150000001413 amino acids Chemical class 0.000 abstract description 3
- 102000004169 proteins and genes Human genes 0.000 description 18
- 238000001514 detection method Methods 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 238000000605 extraction Methods 0.000 description 11
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 11
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 10
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000001962 electrophoresis Methods 0.000 description 9
- 108010081589 Becaplermin Proteins 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 239000006180 TBST buffer Substances 0.000 description 7
- 239000000539 dimer Substances 0.000 description 7
- 239000012460 protein solution Substances 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 6
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 5
- 108700019146 Transgenes Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 108010068370 Glutens Proteins 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 108020003589 5' Untranslated Regions Proteins 0.000 description 3
- 108010022355 Fibroins Proteins 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102100039556 Galectin-4 Human genes 0.000 description 2
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010005233 alanylglutamic acid Proteins 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- HHGYNJRJIINWAK-FXQIFTODSA-N Ala-Ala-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N HHGYNJRJIINWAK-FXQIFTODSA-N 0.000 description 1
- SHYYAQLDNVHPFT-DLOVCJGASA-N Ala-Asn-Phe Chemical compound C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SHYYAQLDNVHPFT-DLOVCJGASA-N 0.000 description 1
- XAGIMRPOEJSYER-CIUDSAMLSA-N Ala-Cys-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)O)N XAGIMRPOEJSYER-CIUDSAMLSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- XEPSCVXTCUUHDT-AVGNSLFASA-N Arg-Arg-Leu Natural products CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCCN=C(N)N XEPSCVXTCUUHDT-AVGNSLFASA-N 0.000 description 1
- JVMKBJNSRZWDBO-FXQIFTODSA-N Arg-Cys-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O JVMKBJNSRZWDBO-FXQIFTODSA-N 0.000 description 1
- DNUKXVMPARLPFN-XUXIUFHCSA-N Arg-Leu-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O DNUKXVMPARLPFN-XUXIUFHCSA-N 0.000 description 1
- BNYNOWJESJJIOI-XUXIUFHCSA-N Arg-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)N BNYNOWJESJJIOI-XUXIUFHCSA-N 0.000 description 1
- SYFHFLGAROUHNT-VEVYYDQMSA-N Arg-Thr-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O SYFHFLGAROUHNT-VEVYYDQMSA-N 0.000 description 1
- AUZAXCPWMDBWEE-HJGDQZAQSA-N Arg-Thr-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O AUZAXCPWMDBWEE-HJGDQZAQSA-N 0.000 description 1
- HAJWYALLJIATCX-FXQIFTODSA-N Asn-Asn-Arg Chemical compound C(C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N)CN=C(N)N HAJWYALLJIATCX-FXQIFTODSA-N 0.000 description 1
- LTDGPJKGJDIBQD-LAEOZQHASA-N Asn-Val-Gln Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O LTDGPJKGJDIBQD-LAEOZQHASA-N 0.000 description 1
- 241000255783 Bombycidae Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- QLCPDGRAEJSYQM-LPEHRKFASA-N Cys-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)N)C(=O)O QLCPDGRAEJSYQM-LPEHRKFASA-N 0.000 description 1
- BDWIZLQVVWQMTB-XKBZYTNZSA-N Cys-Glu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CS)N)O BDWIZLQVVWQMTB-XKBZYTNZSA-N 0.000 description 1
- MXZYQNJCBVJHSR-KATARQTJSA-N Cys-Lys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N)O MXZYQNJCBVJHSR-KATARQTJSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- ZFBBMCKQSNJZSN-AUTRQRHGSA-N Gln-Val-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZFBBMCKQSNJZSN-AUTRQRHGSA-N 0.000 description 1
- RTOOAKXIJADOLL-GUBZILKMSA-N Glu-Asp-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)N RTOOAKXIJADOLL-GUBZILKMSA-N 0.000 description 1
- INGJLBQKTRJLFO-UKJIMTQDSA-N Glu-Ile-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(O)=O INGJLBQKTRJLFO-UKJIMTQDSA-N 0.000 description 1
- QJVZSVUYZFYLFQ-CIUDSAMLSA-N Glu-Pro-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O QJVZSVUYZFYLFQ-CIUDSAMLSA-N 0.000 description 1
- NMROINAYXCACKF-WHFBIAKZSA-N Gly-Cys-Cys Chemical compound NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(O)=O NMROINAYXCACKF-WHFBIAKZSA-N 0.000 description 1
- WNGHUXFWEWTKAO-YUMQZZPRSA-N Gly-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN WNGHUXFWEWTKAO-YUMQZZPRSA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- LRAUKBMYHHNADU-DKIMLUQUSA-N Ile-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@@H](C)CC)CC1=CC=CC=C1 LRAUKBMYHHNADU-DKIMLUQUSA-N 0.000 description 1
- JHNJNTMTZHEDLJ-NAKRPEOUSA-N Ile-Ser-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O JHNJNTMTZHEDLJ-NAKRPEOUSA-N 0.000 description 1
- IBMVEYRWAWIOTN-UHFFFAOYSA-N L-Leucyl-L-Arginyl-L-Proline Natural products CC(C)CC(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O IBMVEYRWAWIOTN-UHFFFAOYSA-N 0.000 description 1
- IBMVEYRWAWIOTN-RWMBFGLXSA-N Leu-Arg-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(O)=O IBMVEYRWAWIOTN-RWMBFGLXSA-N 0.000 description 1
- NTXYXFDMIHXTHE-WDSOQIARSA-N Leu-Val-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 NTXYXFDMIHXTHE-WDSOQIARSA-N 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- KNKHAVVBVXKOGX-JXUBOQSCSA-N Lys-Ala-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KNKHAVVBVXKOGX-JXUBOQSCSA-N 0.000 description 1
- YXPJCVNIDDKGOE-MELADBBJSA-N Lys-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)N)C(=O)O YXPJCVNIDDKGOE-MELADBBJSA-N 0.000 description 1
- FZUNSVYYPYJYAP-NAKRPEOUSA-N Met-Ile-Ala Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O FZUNSVYYPYJYAP-NAKRPEOUSA-N 0.000 description 1
- HLZORBMOISUNIV-DCAQKATOSA-N Met-Ser-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C HLZORBMOISUNIV-DCAQKATOSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- HWLKHNDRXWTFTN-GUBZILKMSA-N Pro-Pro-Cys Chemical compound C1C[C@H](NC1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CS)C(=O)O HWLKHNDRXWTFTN-GUBZILKMSA-N 0.000 description 1
- YDTUEBLEAVANFH-RCWTZXSCSA-N Pro-Val-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 YDTUEBLEAVANFH-RCWTZXSCSA-N 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- XOWKUMFHEZLKLT-CIQUZCHMSA-N Thr-Ile-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O XOWKUMFHEZLKLT-CIQUZCHMSA-N 0.000 description 1
- UZDHNIJRRTUKKC-DLOVCJGASA-N Val-Gln-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)O)N UZDHNIJRRTUKKC-DLOVCJGASA-N 0.000 description 1
- UEHRGZCNLSWGHK-DLOVCJGASA-N Val-Glu-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UEHRGZCNLSWGHK-DLOVCJGASA-N 0.000 description 1
- YLRAFVVWZRSZQC-DZKIICNBSA-N Val-Phe-Glu Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N YLRAFVVWZRSZQC-DZKIICNBSA-N 0.000 description 1
- LCHZBEUVGAVMKS-RHYQMDGZSA-N Val-Thr-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(O)=O LCHZBEUVGAVMKS-RHYQMDGZSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 108010080488 arginyl-arginyl-leucine Proteins 0.000 description 1
- 108010060035 arginylproline Proteins 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000005014 ectopic expression Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 108010021843 fluorescent protein 583 Proteins 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 108010073628 glutamyl-valyl-phenylalanine Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 108010064486 phenylalanyl-leucyl-valine Proteins 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108010015796 prolylisoleucine Proteins 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 108010084932 tryptophyl-proline Proteins 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/49—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
- A01K67/0333—Genetically modified invertebrates, e.g. transgenic, polyploid
- A01K67/0337—Genetically modified Arthropods
- A01K67/0339—Genetically modified insects, e.g. Drosophila melanogaster, medfly
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/05—Animals modified by non-integrating nucleic acids, e.g. antisense, RNAi, morpholino, episomal vector, for non-therapeutic purpose
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/70—Invertebrates
- A01K2227/706—Insects, e.g. Drosophila melanogaster, medfly
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/103—Plasmid DNA for invertebrates
- C12N2800/105—Plasmid DNA for invertebrates for insects
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Environmental Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明涉及适用于家蚕表达的改造血小板衍生生长因子基因及其表达载体和应用,改造血小板衍生生长因子基因的核苷酸序列如SEQ ID NO.1第7~399位所示,其编码的氨基酸如SEQ ID NO.2所示,将改造血小板衍生生长因子基因与分泌型丝胶1基因启动子和分泌型丝胶1基因终止子构成表达框,并用增强子hr3增强表达,同时连入piggyBac转座臂和荧光筛选标记基因构建表达系统,该表达系统能够在家蚕丝腺中高效表达重组血小板衍生生长因子,并且具有生物活性,能够用于大规模生产重组血小板衍生生长因子,具有良好的市场前景。
Description
技术领域
本发明属于生物技术领域,特别涉及适用于家蚕表达的改造血小板衍生生长因子基因,还涉及表达该因子的表达载体和应用。
背景技术
随着社会的发展,生产重组蛋白的需求越来越高。但目前对重组蛋白的大量需求来说,所能提供的重组蛋白产量是远远不够的。转基因家蚕丝腺生物反应器是利用家蚕丝腺表达重组蛋白的转基因动物表达系统。
家蚕属于鳞翅目蚕蛾科,经过长达五千年的人工驯养、选育,已丧失飞翔逃逸能力,是一种非常安全的转基因动物,不必担心转基因家蚕飞翔逃逸室外的风险;同时在丝蛋白合成、分泌方面具有强大的能力,在蚕5龄期的5~6天内,丝腺体重可增加20多倍,合成丝蛋白质的量占整个蚕体蛋白质总量的70%以上。除此之外,家蚕具有生长周期短,遗传背景清晰,具有蛋白质翻译后修饰的功能,饲养成本低和可规模化饲养的独特优势。随着家蚕转基因技术体系的建立和应用,以家蚕丝腺作为生物反应器大规模、低成本生产高附加值的有用蛋白,具有广阔的应用前景,值得高度关注。
早在20世纪40年代,就有研究人员开始了家蚕转基因体系前期研究探索的相关工作,直至2000年,受piggyBac转座子成功应用于果蝇转基因研究的启示,Tamura等人利用显微注射家蚕胚胎的方法将携带有绿色荧光蛋白(EGFP)报告基因的piggyBac转座表达载体导入家蚕早期胚胎,并在G1代蚕卵中成功获得了表达EGFP的转基因蚕。随后,Thomas等将神经复眼组织特异性启动子的绿色荧光蛋白基因遗传标记(3XP3-EGFP)应用到家蚕转基因遗传筛选中,简化了转基因家蚕的制备流程,提高了转基因的筛选效率。利用该转基因技术,建立了包括丝素表达系统及丝胶表达系统在内的多种表达系统。丝胶蛋白由中部丝腺细胞合成分泌,易溶于水,包裹在丝素纤维外层。因此,外源蛋白表达在丝胶层将比表达在丝素层更容易分离纯化。2007年,Tomita等利用家蚕丝胶1基因(Ser1)启动子建立了Ser1表达系统,由300bp的Ser1启动子调控EGFP基因在丝胶层的分泌表达,并利用源自杆状病毒的反式调控元件IE1和增强子元件hr3激活Ser1启动子的活性,使得EGFP的表达水平增加10 倍,占茧层质量的0.7%。随后Iizuka等利用BmNPVpol基因的5'端非翻译区(5'-UTR)对该系统进行优化,使外源蛋白EGFP的翻译效率提高2倍。但是,hr3/IE1会破坏Ser1启动子的组织特异性,导致标记基因与外源基因异位表达,进而引起转基因家蚕死亡。2009年, Tatematsu等利用GAL4/UAS双元表达系统建立高效丝胶表达系统,构建了由Ser1启动子调控表达GAL4的转基因家蚕,然后构建UAS调控的EGFP转基因家蚕,通过2个转基因家蚕品系的杂交,实现EGFP在中部丝腺组织的特异表达,随后,他们又进一步对UAS的5'-UTR、信号肽编码序列等进行优化,提高了EGFP的转录和翻译效率,使蚕体中EGFP蛋白的产量得到显著提高,达到500μg/头。2013年,Wang等报告了一种更为高效的Ser1表达系统hSRSE,该系统由Ser1基因528bp的启动子,58bp完整的5'-UTR以及87bp的信号肽编码序列构成。为提高表达效率,又利用hr3CQ增强子以及Ser1基因的3'-UTR(Ser1PA)优化了Ser1表达系统,使得重组红色荧光蛋白(DsRed)的产量提高16倍,达到茧层质量的9.5%,这也是目前已报告的表达效率最高的Ser1表达系统。以上3类高效的Ser1表达系统为在中部丝腺进行重组表达外源蛋白提供了有力的支撑。
人血小板衍生生长因子是存在于血小板颗粒中的碱性蛋白质,具有A、B、C、D四种亚基,由两条相同或不同的的多肽链形成同型或异型二聚体发挥作用。B链单体大小约为14kD,由两条B链形成的二聚体PDGF-BB可在多条通路中发挥作用,是人体内的主要存在形式。 PDGF具有多种功效,因此在医学美容等方面都具有广阔的应用前景。在医学上,PDGF由于具有促进伤口愈合的作用,对于烧伤患者及皮肤病患者是一剂良药。当出现伤口时,多种细胞均可释放PDGF,如血管发生破裂可血小板释放出多种生长因子,其中包括PDGF,PDGF可刺激邻近的结缔组织细胞生长,而结缔组织是重建受损组织、愈合创口的先锋队。因此PDGF在伤口愈合过程中发挥重要作用。同时,PDGF在美容行业也是祛皱抗衰的良药,这是由于PDGF具有的血管再生重塑的作用,PDGF可促进皮下血管形成,修复皮下血液微循环系统,为皮肤提供充足营养,还可以促进胶原蛋白的合成,延缓皮肤衰老。PDGF是一种重要的促有丝分裂因子,可促进多种细胞群分裂增殖,从而使皱纹自然长平。因此,利用转基因重组技术生产PDGF-BB蛋白可作为蛋白的新来源,有望出现新的应用形式,具有巨大的开发前景。
发明内容
有鉴于此,本发明的目的之一在于提供适用于家蚕表达的改造血小板衍生生长因子基因;本发明的目的之二在于提供含有所述适用于家蚕表达的改造血小板衍生生长因子基因的表达载体;本发明的目的之三在于提供所述表达载体在家蚕丝腺表达重组血小板衍生生长因子中的应用;本发明的目的之四在于提供利用所述表达载体表达重组血小板衍生生长因子的方法。
为实现上述发明目的,本发明提供如下技术方案:
1、适用于家蚕表达的改造血小板衍生生长因子,所述改造血小板衍生生长因子的核苷酸序列如SEQ ID NO.1第7~399位所示。
2、含有所述适用于家蚕表达的改造血小板衍生生长因子基因的表达载体。
优选的,所述表达载体依次含有增强子hr3,分泌型丝胶1基因启动子、5`端非翻译区、信号肽、改造血小板衍生生长因子基因和丝胶1基因的终止子。
优选的,所述表达载体还含有荧光筛选标记基因表达框,所述荧光筛选标记基因表达框位于所述增强子hr3上游。
优选的,所述表达载体由SEQ ID NO.1所示序列连入SEQ ID NO.3所示序列的BamHI 和NotI酶切位点处,再用AscI酶切后连入经相同酶切的pBac{3xp3EGFPaf}载体中。
3、所述表达载体在家蚕丝腺表达重组血小板衍生生长因子中的应用。
4、利用所述表达载体表达重组血小板衍生生长因子的方法,包括如下步骤:将所述表达载体注射已解除滞育的家蚕蚕卵,用无毒胶水封口后经甲醛蒸汽消毒,孵化,至成虫后进行自交或回交制种,筛选转基因阳性蛾圈,取阳性转基因家蚕茧壳,粉碎成粉末,然后溶解于含8M Urea、50mM Tris-Cl、pH 8.0的缓冲液中,80℃水浴30min,离心收集上清,经纯化,得重组血小板衍生生长因子。
优选的,茧壳粉末溶解于缓冲液中茧壳粉末的浓度为30mg/mL。
更优选的,所述纯化的具体方法为:将上清液过0.45uM滤膜后,用肝素亲和柱HiTrapTM Heparin HP过柱,用含0~1000mM NaCl的洗脱液洗脱,洗脱液再过阳离子交换柱HiTrapTM SP HP,并用含0~1000mM NaCl的洗脱液洗脱,最后再过阴离子交换柱HiTrapTM QHP,收集流穿液,即为纯化后的重组血小板衍生生长因子。
本发明的有益效果在于:本发明公开了适用于家蚕表达的改造血小板衍生生长因子基因,利用前期建立的高效丝胶1表达系统驱动人血小板衍生生长因子在家蚕中部丝腺特异表达,对重组人血小板衍生生长因子的表达进行分子检测及活性鉴定,获得具有生物学活性的重组血小板衍生生长因子,为大规模生产血小板衍生生长因子提供了可能,并为探索转基因家蚕丝腺生物反应器实用化提供了更多的证据。
附图说明
为了使本发明的目的、技术方案和有益效果更加清楚,本发明提供如下附图进行说明:
图1为转基因表达载体结构及荧光筛选(A:转基因表达载体结构示意图:3xp3EGFP表示转基因荧光筛选标记基因;hr3CQ表示增强子hr3;Ser1Pro表示分泌型丝胶1基因启动子;5`UTR表示5`端非翻译区;SP表示信号肽;PDGF-BB表示经过密码子优化设计的人血小板衍生生长因子基因编码序列;Ser1PA表示丝胶1基因的终止子;ITR表示piggyBac转座臂序列;B:蚕卵荧光图;C:蚕卵白光图;D:蛾荧光图;E:蛾白光图)。
图2为PDGF家蚕茧壳蛋白SDS-PAGE电泳图及Western Blot检测图(WT:正常茧壳蛋白;1-15:转基因阳性个体茧壳蛋白)。
图3为重组PDGF蛋白二聚体的检测(A:SDS-PAGE电泳图;B:WesternBlot检测图。1:WT蚕茧提取的蛋白溶液非还原电泳检测;2:WT蚕茧提取的蛋白溶液还原电泳检测;3:PDGF蚕茧提取的蛋白溶液非还原电泳检测;4:PDGF蚕茧提取的蛋白溶液还原电泳检测。图中黑色箭头所示为PDGF-B单体,红色箭头所示为PDGF-BB二聚体形式)。
图4PDGF蛋白纯化(M:蛋白预染Maker;A:肝素柱纯化结果:1:WT蛋白原液;2: PDGF蛋白原液;3:PDGF蛋白肝素亲和柱流穿液;4:100mM NaCl;5:150mM NaCl;6: 200mM NaCl;7:250mM NaCl;8:300mM NaCl;9:500mM NaCl;10:1M NaCl;B:阳离子交换柱纯化结果:1:PDGF蛋白原液(100mM NaCl);2:阳离子交换柱流穿液;3: 150mM NaCl;4:200mM NaCl;5:400mM NaCl;6:600mM NaCl;7:800mM NaCl;8: 1M NaCl;C:阴离子交换柱纯化结果:1:PDGF蛋白原液(150mM NaCl);2:阴离子交换柱流穿液;D:PDGF蛋白SDS-PAGE电泳及WesternBlot结果图:1:PDGF蛋白纯化样品;2:PDGF蛋白标准品)。
图5为纯化的PDGF重组蛋白促进NIH3T3细胞增殖。
图6为纯化的PDGF重组蛋白促进NIH3T3细胞迁移(A:24h后的划痕面积对比;B:新迁移出的细胞数量)。
具体实施方式
下面将结合附图,对本发明的优选实施例进行详细的描述。
本发明使用的实验材料如下:供试家蚕品种大造(P50)由本实验室保存。幼虫在25℃人工气候箱中以人工饲料饲养。小鼠胚胎成纤维细胞NIH3T3由本实验室保存,并培养于含有 10%(v/v)胎牛血清(FBS,Gibco)的DMEM培养基中,培养条件为37℃,5%CO2。质粒载体pSLfa1180fa、pBac{3xp3EGFPaf},pBac{3xp3DsRedaf}由本实验室保存。
主要试剂及溶液的配制如下:分子克隆过程中所用到的常规培养基,试剂缓冲液等参照《分子克隆实验指南第三版译》以及《TaKaRa商品目录》中实验室常规试剂配制方法章节 (S1-S11)进行配置。DNA聚合酶Ex-Taq,LA-Taq Kit,常规限制性内切酶,碱性磷酸酶,测序克隆载体pMD19-T simple载体Kit,DNA Ligation Kit Ver.2.0,荧光定量PCR试剂盒SYBR premix Ex TaqTM均购自TaKaRa公司。转化用大肠杆菌感受态细胞Trans1-T1,常规质粒DNA 提取试剂盒Easypure Plasmid MiniPrep Kit购自全式金公司。琼脂糖凝胶DNA回收试剂盒Gel Extraction Mini Kit(50)购自华舜生物科技公司。转基因注射用超纯质粒提取试剂盒QIA prep Spin Miniprep Kit(50)购自QIAGEN。Total RNA Kit II(50)试剂盒购自Omega Bio-Tec公司。人(PDGF)蛋白多克隆抗体anti-rhPDGF antibody、重组人血小板衍生生长因子蛋白标准品rhPDGF-std均购自abcam公司,细胞增殖检测CCK-8试剂盒购自碧云天公司。
实施例1、基因的合成
从NCBI下载人血小板衍生生长因子蛋白(HumanPlatelet Derived GrowthFactor subunit B,hPDGFB,GenBank:NM_002608.3)成熟肽氨基酸序列,根据家蚕密码子使用偏好型进行优化设计编码序列,其核苷酸如SEQ ID NO.1第7~399位所示,上游设计BamHI,下游设计 NotI酶切位点,其编码的氨基酸序列如SEQ ID NO.2所示,由公司合成SEQID NO.1所示基因序列。
实施例2、转基因载体的构建
将商业合成的PDGF基因编码序列通过BamHI和NotI酶切位点构建到 psl1180[hr3CQSer1spDsRedSerPA](SEQ ID NO.3)中,形成psl1180[hr3CQSer1spPDGFSer1],再通过AscI位点构建到pBac{3xp3EGFPaf}载体的AscI位点中,形成转基因表达载体 pBac{3xp3EGFP,hSPDGF-BBSer1PA},命名为phPDGFSer1,结构如图1中A所示。
实施例3、显微注射与荧光筛选
利用QIAGEN Plasimd Mini Kit质粒抽提试剂盒提取转基因表达载体phPDGFSer1以及辅助载体pHA3PIG质粒,将各质粒浓度稀释至400ng/μl,并按1∶1摩尔比分别与辅助载体 pHA3PIG质粒进行混合。将混合后的质粒注射已解除滞育的大造早期胚胎(产卵后2~5h),随后用无毒胶水对注射孔进行封口,经35%的甲醛蒸汽消毒5分钟后,置于25℃,相对湿度 85%的环境中孵化,孵化的幼虫(G0代)采用人工饲料饲育,至成虫后进行自交或回交制种,获得的G1代蚕卵(第7天)在宏观体视荧光显微镜(Olypus MVX10,日本)下检测,绿色荧光观察采用波长为460~550nm的激发光,筛选出在眼睛或神经特异激发绿色荧光的转基因阳性蛾圈,并命名为PDGF,如图1中B~E所示。转基因家蚕的荧光筛选统计见表1,其中从PDGF的13个G1代蛾圈中总共筛选到5个阳性蛾圈,阳性率为38%。
表1、转基因筛选统计表
实施例4、SDS-PAGE与WesternBlot检测
将重组PDGF转基因家蚕的G1代5个不同的阳性蛾圈中的阳性个体分别单独饲养,并对上蔟后获得的26个阳性个体的茧壳进行重组蛋白的SDS-PAGE检测,检测方法如下:茧壳总蛋白中重组蛋白的提取和检测方法如下,将茧壳于液氮中浸泡直至变脆,使用粉碎机粉碎成粉末,按照30mg/ml的茧壳浓度溶于8MUrea,50mMTris-Cl,pH8.0,的缓冲液中,80℃水浴30min,室温下13400rpm/min离心10min收集上清。经萃取的茧壳总蛋白进行12% SDS-Page电泳检测,考马斯亮蓝染色,同时将萃取的总蛋白经12%SDS-Page胶电泳分离后,采用电转膜法将SDS-PAGE胶中的蛋白转移至PVDF膜上。PVDF膜置于含5%脱脂奶粉的 TBST缓冲液中,4℃过夜封闭。免疫杂交前,于室温利用TBST清洗PVDF膜3次,每次5min。利用含5%脱脂奶粉的TBST按1:1000稀释配置抗rhPDGF(abcam)一抗杂交液,将PVDF 膜浸入杂交液中室温振荡孵育2h,TBST清洗5次,每次10min。利用TBST按1:20000稀释比例配置HRP标记的羊抗兔二抗(购自碧云天公司)杂交液,将TBST清洗后的PVDF膜浸入二抗杂交液中于室温振荡孵育2h,TBST清洗5次,每次10min。将清洗后的PVDF膜置于干净的保鲜膜上,将ECL显色液(Amersham Biosciences)均匀滴在PDVF膜面上,室温避光孵育5min,利用ChemiscopeSeries(Clinx science instruments)仪器进行曝光和成像,结果如图2所示。显示:转基因茧壳蛋白泳道在14kDa分子Marker处出现差异条带,与PDGF-BB 蛋白的理论分子量大小一致,并且差异条带在不同的转基因个体来源的茧壳总蛋白中的含量明显不同。为进一步鉴定此特异性条带为PDGF,同时进行Western blot检测(图3),结果显示:转基因茧壳蛋白在14kDa分子Marker处出现的差异条带可以与PDGF的抗体发生特异的反应,此结果证实该差异条带即是转基因家蚕特异表达的PDGF蛋白。进一步,通过对泳道中的蛋白进行灰度比对,推算出蚕丝中PDGF蛋白的含量大约占到溶出蛋白含量的10%。以上结果表明,本研究建立的Ser1表达系统可以高效的重组生产人PDGF蛋白,并分泌到家蚕蚕丝中。此外,重组蛋白在不同阳性蛾圈的个体中的含量具有显著的差异,暗示着转PDGF 基因家蚕在丝腺细胞中的表达受到强烈的染色体位置效应的影响。
PDGF蛋白发挥作用是,是以二聚体的形式激活受体,受体被激活后发生磷酸化,经过 ERK信号通路将信号传递至核内,引起受体细胞的增殖和迁移。因此PDGF蛋白想要发挥活性的前提是以二聚体的形式存在。为了探究本实验中采取的提取方法是否影响蛋白的二聚体形式,我们对提取出的蛋白聚体结构进行了检测。使用还原剂β-巯基乙醇处理和不使用β- 巯基乙醇电泳的结果显示,在不添加还原剂的条件下可以检测到二聚体的存在(图3),说明使用8M尿素高温提取丝胶蛋白的方法不影响PDGF蛋白二聚体的形成,可进行下一步的纯化。
实施例5、PDGF-BB的分离纯化
取粉碎后的PDGF转基因蚕茧按30mg/ml溶于8MUrea,50mMTris-Cl,pH8.0的缓冲液中,80℃水浴30min,13500rpm,25℃离心15min收集上清,再经过0.45uM滤膜过滤得到可用于过柱的上清液。根据PDGF蛋白具有肝素结合域的结构特点,上清首先经过肝素亲和柱HiTrapTM Heparin HP(GE healthcare),然后用不同浓度NaCl洗脱液(8MUrea,50mMTris-Cl, pH6.0配制,NaCl浓度为0、100、150、200、250、300、500、1000mM)洗脱收集,样品收集后进行12%SDS-PAGE检测其纯度,得到纯度约为30%的PDGF蛋白溶液(图4中A所示)。为了进一步提高PDGF的纯度,利用PDGF在溶液中带正电荷的性质,再经过阳离子交换柱 HiTrapTMSP HP(GE healthcare),用不同浓度NaCl洗脱液(8M Urea,50mMTris-Cl,pH6.0 配制,NaCl浓度为0、150、200、400、800、1000mM)洗脱收集,样品收集后进行12%SDS-PAGE 检测其纯度,得到纯度约为50%的PDGF蛋白溶液(图4,B)。最后再经过阴离子交换柱 HiTrapTM Q HP收集流穿液,进行12%SDS-PAGE检测其纯度,最终得到纯度约为80%的PDGF 蛋白溶液(图4,C)。将纯化的蛋白进行Western blot检测,结果如图4中D所示。结果表明纯化后的蛋白为PDGF蛋白。
实施例6、重组蛋白活性的鉴定
PDGF蛋白具有促进细胞增殖与迁移的活性。利用商业化PDGF-BB蛋白作为阳性对照,对纯化获得的PDGF蛋白进行增殖活性鉴定,将纯化后的PDGF蛋白与等质量的PDGF标准品一起处理饥饿12h后的NIH3T3细胞24h,增殖结果显示,纯化得到的PDGF蛋白处理后的NIH3T3细胞数量明显多于对照相,且与标准品相比无明显差异,说明纯化得到的PDGF 蛋白具有促进细胞增殖的活性(图5)。同样的,利用商业化PDGF-BB蛋白作为阳性对照,对纯化获得的PDGF蛋白进行迁移活性的鉴定。在长满NIH3T3细胞的孔内对细胞进行饥饿处理12h,划痕后加入纯化后的PDGF蛋白与等质量的PDGF标准品,24h后结果显示,纯化后的PDGF蛋白处理的NIH3T3细胞孔内划痕面积与对照组相比明显减小(图6,A),划痕处新增长的细胞数量明显多于对照组,说明纯化得到的PDGF蛋白具有促进细胞迁移的活性 (图6,B)。
最后说明的是,以上优选实施例仅用以说明本发明的技术方案而非限制,尽管通过上述优选实施例已经对本发明进行了详细的描述,但本领域技术人员应当理解,可以在形式上和细节上对其作出各种各样的改变,而不偏离本发明权利要求书所限定的范围。
序列表
<110> 西南大学
<120> 适用于家蚕表达的改造血小板衍生生长因子基因及其表达载体和应用
<160> 3
<170> SIPOSequenceListing 1.0
<210> 1
<211> 347
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 1
ggatccatga gcctgggtag cctgaccata gcggagcctg ccatgattgc ggaatgtaaa 60
actcgtactg aagtctttga aataagccgt aggttaatag acagaacaaa cgctaatttc 120
ctggtctggc ctccatgcgt ggaagttcaa cgctgttcag gttgctgtaa caatagaaac 180
gtgcagtgcc gcccgacaca agttcagttg cgtcccgtcc aagtaaggaa aatcgagata 240
gtcagaaaaa agcctatctt caagaaggcc actgtaactt tggaagacca cttggcctgt 300
aaatgcgaaa cggttgctgc tgctcgtcct gtcacctaag cggccgc 347
<210> 2
<211> 110
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 2
Met Ser Leu Gly Ser Leu Thr Ile Ala Glu Pro Ala Met Ile Ala Glu
1 5 10 15
Cys Lys Thr Arg Thr Glu Val Phe Glu Ile Ser Arg Arg Leu Ile Asp
20 25 30
Arg Thr Asn Ala Asn Phe Leu Val Trp Pro Pro Cys Val Glu Val Gln
35 40 45
Arg Cys Ser Gly Cys Cys Asn Asn Arg Asn Val Gln Cys Arg Pro Thr
50 55 60
Gln Val Gln Leu Arg Pro Val Gln Val Arg Lys Ile Glu Ile Val Arg
65 70 75 80
Lys Lys Pro Ile Phe Lys Lys Ala Thr Val Thr Leu Glu Asp His Leu
85 90 95
Ala Cys Lys Cys Glu Thr Val Ala Ala Ala Arg Pro Val Thr
100 105 110
<210> 3
<211> 2036
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 3
ccatggcagc gtcgtgaaaa gaggcaatga caaatacaaa acgacgtatg agcagacccg 60
tcgccaagac gggtctacct ctaagatgat gtcatttgtt ttttaaaact aactcgcttt 120
acgagtagaa ttctacgtgt aaaacataat caagagatga tgtcatttgt ttttcaaaac 180
caaactcgct ttacgagtag aattctacgt gtaaaacaca atcaaaagat gatgtcattc 240
gtttttcaaa accgaattta agaaatgatg tcatttgttt ttcaaaacca aactcgcttt 300
acgagcagaa ttctacgtgt aaaacacaat caagagatga tgtcatttgt ttttcaaaac 360
tgaatgatgt catttgtttt tcaaaactaa acttgctttg cgagtagaat tctacgtgta 420
aaacacagtc aagagatgat gtcatttgtt tttcaaaact gaaccggctt tacgagtaga 480
attctacttg taaaacataa tcaagagatg atgtcatttg tttttcaaaa ctgaactggc 540
tttacgagta gaattctacg tgtaaaacat aatcaagaga tgatgtcatc attaaactga 600
tgtcatttta tacacgattg ttaacatgtt taataatgac taatttgttt ttccaaatta 660
aactcgcttt acgagtagaa ttctacttgt aacgcacgat taagtatgaa tcataagctg 720
atgtcatttg ttttcgacat aaaatgttta tacaatggaa tcttcttgta aattatccaa 780
ataatataat ttatccgatt ctacgttaca tttaaattcg ttgttatcgt acaattcttc 840
aggacacgcc atgtattggt catttttagc gtgcaaccaa cgattgtatt tgacgccgtc 900
gttggattgc gtgttcaggt tggcgtacac gtgactgggc acggcttctt tttccatggg 960
acgtcgacga aaacagcaca cacactacat accatgtatt tgacgcacac acgcatgtat 1020
actatttatt gtcaaacttt tgttcttgac gtctgtgttc aaactgagaa tagattaaat 1080
attgtttgtc tttattaata ttttttaata gtgtagtctt ggcgaaattt gtgattataa 1140
aagtataaaa tacaatcata atagtgtacg aacttacaat tccaattaat tatagtcgaa 1200
tttcgactac tgcgggacct ctagtattaa taattctctt taaaaaaaaa cagagcatca 1260
aatactgcac aaatgtcaag cgggtctcaa cgagccatga ataaattaga aatcaattaa 1320
taacataaaa taggcaaaca aaataaaacc atttacatag agaacgtttg ttgaacaaaa 1380
acaataactt gtatacattg tttgcacaaa tgtttgaagc gaaaatttat tactctctac 1440
gtaagcttga tcaaacttcg ttttcgtata aaacgcgttg gcccaaccac tttggcatag 1500
tcgtcttatc atcgggtctc taaggatcaa gcgatccaaa gaccgccaac atgcgtttcg 1560
ttctgtgctg cactttgatt gcgttggctg cgctcagcgt aaaagccttc ggtcaccacc 1620
ccggcaatcg agatacagga tccgcggccg ctacaactaa acacgacttg gagtattcct 1680
tgtagtgttt aagattttaa atcttactta atgacttcga acgattttaa cgataacttt 1740
ctctttgttt aactttaatc agcatacata aaaagccccg gttttgtatc gggaagaaaa 1800
aaaatgtaat tgtgttgcct agataataaa cgtattatca aagtgtgtgg ttttccttta 1860
ccaaagaccc ctttaagatg ggcctaatgg gcttaagtcg agtcctttcc gatgtgttaa 1920
atacacattt attacactga tgcgtcgaat gtacactttt aataggatag ctccactaaa 1980
aattatttta tttatttaat ttgttgcacc aaaactgata cattgacgaa aagctt 2036
Claims (9)
1.适用于家蚕表达的改造血小板衍生生长因子基因,其特征在于:所述改造血小板衍生生长因子基因的核苷酸序列如SEQ ID NO.1第7~399位所示。
2.含有权利要求1所述适用于家蚕表达的改造血小板衍生生长因子基因的表达载体。
3.根据权利要求2所述的表达载体,其特征在于:所述表达载体依次含有增强子hr3,分泌型丝胶1基因启动子、5`端非翻译区、信号肽、改造血小板衍生生长因子基因和丝胶1基因的终止子。
4.根据权利要求3所述的表达载体,其特征在于:所述表达载体还含有荧光筛选标记基因表达框,所述荧光筛选标记基因表达框位于所述增强子hr3上游。
5.根据权利要求2或3所述的表达载体,其特征在于:所述表达载体由SEQ ID NO.1所示序列连入SEQ ID NO.3所示序列的BamHI和NotI酶切位点处,再用AscI酶切后连入经相同酶切的pBac{3xp3EGFPaf}载体中。
6.权利要求3~5任一项所述表达载体在家蚕丝腺表达重组血小板衍生生长因子中的应用。
7.利用权利要求3~5任一项所述表达载体表达重组血小板衍生生长因子的方法,其特征在于,包括如下步骤:将所述表达载体注射已解除滞育的家蚕蚕卵,用无毒胶水封口后经甲醛蒸汽消毒,孵化,至成虫后进行自交或回交制种,筛选转基因阳性蛾圈,取阳性转基因家蚕茧壳,粉碎成粉末,然后溶解于含8M Urea、50mM Tris-Cl、pH 8.0的缓冲液中,80℃水浴30min,离心收集上清,经纯化,得重组血小板衍生生长因子。
8.根据权利要求6所述的方法,其特征在于:茧壳粉末溶解于缓冲液中茧壳粉末的浓度为30mg/mL。
9.根据权利要求6所述的方法,其特征在于,所述纯化的具体方法为:将上清液过0.45uM滤膜后,用肝素亲和柱HiTrapTM Heparin HP过柱,用含0~1000mM NaCl的洗脱液洗脱,洗脱液再过阳离子交换柱HiTrapTM SP HP,并用含0~1000mM NaCl的洗脱液洗脱,最后再过阴离子交换柱HiTrapTM Q HP,收集流穿液,即为纯化后的重组血小板衍生生长因子。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810344164.4A CN108588083B (zh) | 2018-04-17 | 2018-04-17 | 适用于家蚕表达的改造血小板衍生生长因子基因及其表达载体和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810344164.4A CN108588083B (zh) | 2018-04-17 | 2018-04-17 | 适用于家蚕表达的改造血小板衍生生长因子基因及其表达载体和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108588083A true CN108588083A (zh) | 2018-09-28 |
CN108588083B CN108588083B (zh) | 2021-04-09 |
Family
ID=63623019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810344164.4A Active CN108588083B (zh) | 2018-04-17 | 2018-04-17 | 适用于家蚕表达的改造血小板衍生生长因子基因及其表达载体和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108588083B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110354307A (zh) * | 2019-07-16 | 2019-10-22 | 西南大学 | 基于转人血小板衍生生长因子基因蚕丝的蛋白丝胶凝胶及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1912116A (zh) * | 2006-07-14 | 2007-02-14 | 西南大学 | 利用家蚕丝心蛋白重链启动子大量表达外源蛋白的方法 |
CN103911383A (zh) * | 2014-04-29 | 2014-07-09 | 西南大学 | 适于家蚕丝腺表达的改造人酸性成纤维细胞生长因子基因及其表达系统和应用 |
CN104513821A (zh) * | 2013-09-27 | 2015-04-15 | 西南大学 | 改造的人酸性成纤维细胞生长因子基因及其重组载体和应用 |
CN105861515A (zh) * | 2016-04-27 | 2016-08-17 | 西南大学 | 适于家蚕丝腺表达的改造人血清白蛋白基因及其表达系统和应用 |
-
2018
- 2018-04-17 CN CN201810344164.4A patent/CN108588083B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1912116A (zh) * | 2006-07-14 | 2007-02-14 | 西南大学 | 利用家蚕丝心蛋白重链启动子大量表达外源蛋白的方法 |
CN104513821A (zh) * | 2013-09-27 | 2015-04-15 | 西南大学 | 改造的人酸性成纤维细胞生长因子基因及其重组载体和应用 |
CN103911383A (zh) * | 2014-04-29 | 2014-07-09 | 西南大学 | 适于家蚕丝腺表达的改造人酸性成纤维细胞生长因子基因及其表达系统和应用 |
CN105861515A (zh) * | 2016-04-27 | 2016-08-17 | 西南大学 | 适于家蚕丝腺表达的改造人血清白蛋白基因及其表达系统和应用 |
Non-Patent Citations (2)
Title |
---|
CHEN W等: "Transgenic Silkworm-Based Silk Gland Bioreactor for Large Scale Production of Bioactive Human Platelet-Derived Growth Factor (PDGF-BB) in Silk Cocoons", 《INT J MOL SCI》 * |
KUAI,J等: "登录号:4QCI_C", 《GENBANK》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110354307A (zh) * | 2019-07-16 | 2019-10-22 | 西南大学 | 基于转人血小板衍生生长因子基因蚕丝的蛋白丝胶凝胶及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN108588083B (zh) | 2021-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190185528A1 (en) | Transgenic silkworms capable of producing chimeric spider silk polypeptides and fibers | |
Teulé et al. | Silkworms transformed with chimeric silkworm/spider silk genes spin composite silk fibers with improved mechanical properties | |
CA2624667A1 (en) | Silk proteins containing coiled coil region | |
CN108642059B (zh) | 适用于家蚕表达的改造具有促进细胞增殖因子基因及其表达载体和应用 | |
CN103911383B (zh) | 适于家蚕丝腺表达的改造人酸性成纤维细胞生长因子基因及其表达系统和应用 | |
CN108218972A (zh) | 来自Nephilengys Cruentata蜘蛛、黄带粉趾食鸟蛛和Parawixia Bistriata蜘蛛的网的蛋白 | |
WO2014104269A1 (ja) | 後部絹糸腺遺伝子発現ユニット及びそれを有する遺伝子組換え絹糸虫 | |
CN111793643A (zh) | 表达目的蛋白分布于丝素和丝胶的家蚕丝心蛋白重链表达系统及制备方法和应用 | |
CN109844112A (zh) | 基因重组蓑蛾虫丝 | |
CN104513821B (zh) | 改造的人酸性成纤维细胞生长因子基因及其重组载体和应用 | |
CN111500591B (zh) | 蜘蛛聚状腺丝蛋白基因序列的应用及其改良家蚕丝性能的方法 | |
CN105861515B (zh) | 适于家蚕丝腺表达的改造人血清白蛋白基因及其表达系统和应用 | |
CN111793644A (zh) | 家蚕丝心蛋白重链表达系统及其制备方法和应用 | |
CN108486123B (zh) | 适于家蚕丝腺表达的改造人乳铁蛋白基因及其表达系统和应用 | |
CN108588083A (zh) | 适用于家蚕表达的改造血小板衍生生长因子基因及其表达载体和应用 | |
JP2015505667A (ja) | コラーゲン様絹遺伝子 | |
CN109055386A (zh) | 家蚕BmSCP1基因及其重组表达载体和应用 | |
CN111793645B (zh) | 一种家蚕丝心蛋白重链表达系统及其制备方法和应用 | |
CN108486153A (zh) | FGF2与TGF-β1融合基因在促进蚕丝细胞增殖活性和抗炎功能中的应用及方法 | |
CN116239667B (zh) | 具有促细胞增殖活性的ehEGF重组蛋白及其制备方法和应用 | |
CN107216379A (zh) | 半滑舌鳎igf‑i蛋白及其体外表达制备方法与应用 | |
JPWO2018079861A1 (ja) | 放卵又は放精を誘起するペプチド | |
Sezutsu et al. | Silkworm Transgenesis and its Applications | |
CN101603045B (zh) | 利用家畜乳腺高效生产人溶菌酶 | |
CN112442491A (zh) | 一种家蚕chorion peroxidase基因的克隆表达和纯化方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |